Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) just unveiled an update.
Aurobindo Pharma Limited announced the completion of a US FDA inspection at Unit-IV of its subsidiary, APL Healthcare Limited, located in Andhra Pradesh. The inspection, conducted over ten days, resulted in a ‘Form 483’ issuance with five procedural observations. While these observations will be addressed within the prescribed timelines, the company assured stakeholders that its operations and financials remain unaffected, affirming its commitment to maintaining high manufacturing standards globally.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a prominent pharmaceutical company primarily focused on manufacturing and marketing generic medications and active pharmaceutical ingredients (APIs). The company operates globally, maintaining high standards in healthcare and production processes.
Average Trading Volume: 33,580
Technical Sentiment Signal: Strong Buy
Current Market Cap: 684.3B INR
For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Overview page.